The endothelin B (ETB) receptor agonist IRL 1620 is highly vasoconstrictive in two syngeneic rat tumour lines: potential for selective tumour blood flow modification by Cemazar, M. et al.
The endothelin B (ETB) receptor agonist IRL 1620 is highly
vasoconstrictive in two syngeneic rat tumour lines: potential for
selective tumour blood flow modification
M Cemazar1,2, I Wilson1, VE Prise1, KM Bell1, SA Hill1 and GM Tozer*,1
1Gray Cancer Institute, Mount Vernon Hospital, PO Box 100, Northwood, Middlesex HA6 2JR, UK
The vascular effects of the endothelin B (ETB) receptor agonist IRL 1620 were investigated in the rat P22 carcinosarcoma and a range
of normal tissues in BDIX rats. Tissue blood flow rate was calculated from measurements of tissue uptake of radiolabelled
iodoantipyrine. A comparison of vascular effects in the P22 tumour and the HSN sarcoma growing in CBH/CBi rats was made using
laser Doppler flowmetry, showing similar effects of IRL 1620, with red cell flux rapidly decreasing by 50–60% and then returning to
control levels within approximately 30 min. This corresponded to similar levels but different spatial organisation of ETB binding sites in
the two tumours, as measured by autoradiography. The decrease in tumour blood flow and an increase in vascular resistance suggest
that the vascular component of ETB receptors in the P22 tumour is localised on contractile elements rather than on endothelial cells.
ETA receptors were also identified. Vasoconstriction occurred uniformly throughout the P22 tumour mass, consistent with a
measured homogeneous distribution of ETB receptors. IRL 1620 caused vasoconstriction in normal skeletal muscle, kidney and small
intestine of the BDIX rat as well as in tumour, but did not affect blood flow in other tissues. These effects could be useful for limiting
toxicity of certain chemotherapeutic agents. Fully functional ETB receptors are clearly expressed on tumour vasculature and IRL 1620
shows promise for short-term modification of tumour blood flow. Expression levels of ETB receptors on the tumour vasculature
could be useful for predicting which tumours are likely to respond to IRL 1620.
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Tumour vasculature is morphologically and functionally abnormal
(Carmeliet and Jain, 2000). Therefore, the vascular reactivity of
tumours differs from that of normal tissue, providing the potential
for selective modification of tumour blood flow for therapeutic
benefit (Brown and Giaccia, 1998). Increase in blood flow can
elevate the concentration of antitumour agents reaching tumour
cells and improve oxygenation, with consequent benefit for both
chemotherapy and radiotherapy (Chaplin et al, 1998). However,
most success in this field has come from strategies designed to
damage the tumour vasculature selectively, leading to sustained
blood flow shut-down and consequent tumour cell death (Thorpe
et al, 2003). In addition, vascular dilatation is one of the earliest
steps in angiogenesis (Hudlicka, 1998), so that vasoconstrictors
have potential as antiangiogenic agents. A strategically timed
reduction in blood flow can effectively trap anticancer agents in
tumour tissue (Pedley et al, 2001) and the reduced oxygenation
that accompanies blood flow reduction has potential for activating
the so-called ‘bioreductive’ drugs (Brown, 2002). In order to
control tumour blood flow for therapeutic purposes effectively, it
is essential to understand the mechanisms controlling vascular
tone in tumours.
Endothelin-1 (ET-1), together with ET-2, ET-3 and the ET
receptors (collectively called the endothelin axis), exerts many
important physiological roles in normal tissues, as well as in
cancer (Nelson et al, 2003). Endothelin-1 was first described as a
potent endogenous vasoconstrictor peptide, but is now also known
to play important roles in tissue differentiation, repair, develop-
ment, cell proliferation, hormone production, angiogenesis, matrix
remodelling and apoptosis. It is primarily produced by endothelial,
vascular smooth muscle and epithelial cells and has also been
detected in many different tumours (Bagnato et al, 1999; Kurbel
et al, 1999; Nelson et al, 2003).
The vasoactive action of ET-1 is mediated primarily via
endothelin A (ETA) and endothelin B (ETB) receptors. ETA
receptors are mainly found on vascular smooth muscle cells and
pericytes and these account for the profound vasoconstriction of
ET-1. ETB receptors are found on contractile elements and
endothelial cells and their activation can cause both vasoconstric-
tion (activation of receptors on vascular smooth muscle
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cells/pericytes) and vasodilatation (activation of receptors on
endothelial cells) (Davenport, 2002).
Tumour vasculature is often rather insensitive to vasoactive
agents, presumably due either to a relative lack of vascular smooth
muscle cells supporting the tumour vasculature, a lack of
functional receptors, low binding affinities or lack of downstream
effector mechanisms. However, very few studies have investigated
these factors directly. The endothelin receptor family represents a
group of receptors, which has a profound role in the control of
normal tissue blood flow under both physiological and patholo-
gical conditions (Haynes and Webb, 1994; Russell et al, 1998;
Stjernquist, 1998) and which may be possible to exploit for
selective modification of tumour blood flow (Bell et al, 1996, 1997,
Rai and Gulati, 2003; Sonveaux et al, 2004). The development of
highly specific agonists and antagonists for ET-1 receptors has
provided tools for studying the role of ET-1 in tumour vasculature.
In our previous study on the HSN rat fibrosarcoma, radiotracer
techniques were used to determine blood flow in tumour and
selected normal tissues following systemic treatment with the
selective ETB receptor agonist IRL 1620. Surprisingly, the HSN
tumour vasculature constricted relatively selectively in response to
this agonist compared with the majority of normal tissues, with the
exception of the small intestine (Bell et al, 1999). This unusual
feature of IRL 1620 warranted its study in other tumour types. In
an additional preliminary study using autoradiography in the HSN
tumour, we showed that there were small regions of intense
specific ETB binding sites scattered throughout the tumour mass,
which were suggestive of a vascular localisation of ETB receptors in
this tumour type (Bell et al, 1998).
The main aim of the current study was to continue evaluation of
IRL 1620 as a selective tumour blood flow modifier by extending
studies to a second tumour type (P22 rat carcinosarcoma) and
investigating a full time course of vascular response in tumours vs
normal tissues. Furthermore, the relationship between tumour
vascular response and degree of specific binding sites for IRL 1620
in tumour tissue was investigated. Laser Doppler flowmetry was
used to compare directly the time course of vascular response in
the P22 and HSN tumours.
MATERIALS AND METHODS
Animals and tumours
Early generations of the P22 transplanted rat carcinosarcoma were
grown subcutaneously in the left flank of 10- to 12-week-old male
BDIX rats as described previously (Tozer and Shaffi, 1993).
Tumours were used for experiments when they reached 1– 2 g (all
three orthogonal diameters 10–15 mm, including the skin thick-
ness). Laser Doppler flowmetry studies were also carried out on
early generations of the rat HSN fibrosarcoma grown in the flank
of 8- to 10-week-old female CBH/CBi rats (Bell et al, 1999).
Tumours were used for experiments when they reached 1–2 g in
weight. All experiments were carried out in accordance with the
UK Animal (Scientific Procedures) Act 1986.
Drugs
IRL 1620 ([suc-(Glu9, Ala11,15)-ET-1(8– 21)]), (Alexis, Nottingham,
UK) was dissolved in physiological saline and administered to the
rats by slow bolus intravenous (i.v.) injection, at a dose of
3 nmol kg1 in an injection volume of 4 ml kg1, which was an
effective dose in the HSN tumour model (Bell et al, 1999).
Laser Doppler flowmetry
Red blood cells (RBC) flux was monitored using the Oxford Array
multiple channel laser Doppler system (Oxford Optronics, Oxford,
UK). Rats were anaesthetised by intraperitoneal (i.p.) injection of
fluanisone (10 mg kg1), fentanyl citrate (0.315 mg kg1) (‘Hyp-
norm’, Janssen Animal Health, UK) and midazolam (2 mg kg1)
(‘Hypnovel’, Roche Products Ltd, UK) and kept warm using a
thermostatically controlled heating pad. Five microprobes were
randomly inserted into each tumour through skin incisions, to a
depth of at least 1 mm. After a 20 min stabilisation period, animals
were treated with IRL 1620 and RBC flux was monitored
continuously for 70 min. Measurements were continued for at
least a further 5 min following a lethal injection of anaesthetic to
allow the biological zero RBC flux to be measured. From the 20
readings per second recorded, 3 min averages were calculated for
each probe. After the subtraction of biological zero, the data were
converted to the relative RBC flux, expressed as the percentage of
the RBC flux at time 0 (time of injection of IRL 1620). Mean values
for each animal at each time point were calculated from the
individual probe values and these were used to calculate the overall
mean value for relative RBC flux, at each time point, for the whole
treatment group.
Blood flow
The experimental procedure for the determination of blood flow
using 14C-labelled iodoantipyrine (14C-IAP) (Amersham Life
Sciences, UK) and 125I-labelled iodoantipyrine (125I-IAP) (Institute
of Cancer Research, Sutton, UK) has been described previously
(Tozer and Shaffi, 1993). In brief, rats were anaesthetised and kept
warm, as described above. One tail artery and two tail veins were
catheterised with polyethylene catheters containing heparinised
0.9% saline. Mean arterial blood pressure (MABP) was recorded
throughout by means of a physiological pressure transducer
(Ohmeda, UK) connected to the arterial line.
At different time points (5, 15, 20, 30 min) before the
determination of blood flow, a 3.0 nmol kg1 bolus i.v. injection
of IRL 1620 or saline (drug vehicle in control rats) was
administered to the rat. The rats were heparinised 5 min prior to
blood flow measurement via a venous catheter (0.1 ml of
1000 U ml1 heparin (CP Pharmaceuticals Ltd, UK)). Free flowing
arterial blood was collected into preweighed vials at 1 s intervals,
during a 30 s i.v. infusion of 0.56 MBq (15mCi) 14C-IAP or
0.37 MBq (10 mCi) 125I-IAP prepared in 0.9% saline. Infusion was
achieved via a constant flow infusion pump set at a rate of
1.6 ml min1, which compensated for the blood loss from the
arterial circulation and maintained blood pressure constant
(unpublished data). At 30 s, the rat was rapidly killed by i.v.
injection of Euthatal (0.3 ml) (Rhoˆne Me´rieux Ltd, UK) and the
tumour and selected normal tissues were rapidly excised. When
using 125I-IAP, blood and tissues were weighed and the 125I levels
determined using a Wallac (Bromma, Sweden) Autogamma well
counter. In the case of 14C-IAP blood flow measurements, no
normal tissues were excised. Blood samples were weighed and 10 ml
aliquots were placed in liquid scintillation vials to which 1 ml
Soluene (Canberra-Packard, UK) was added. Vials were left
overnight, and then 10 ml scintillation fluid (Hionic-Fluor,
Canberra-Packard, UK) was added. Radioactivity was determined
by liquid scintillation counting (Beckman LSG 500 multi-purpose
scintillation counter, Fullerton, CA, USA) with suitable quench
correction. Immediately after excision, the tumours were mounted
in Tissue-Tek embedding compound (Raymond Lamb, UK),
frozen in isopentane at 401C and stored at 701C for subsequent
processing. Cryostat sections (20 mm thick) were cut from each
tumour, mounted onto poly-L-lysine-coated slides (Sigma, Poole,
UK) and rapidly dried on a hot plate. Slides were overlaid with
autoradiographic film (Hyperfilm bmax, Amersham, UK) for up to
2 weeks, alongside 14C-labelled methylmethacrylate microscales
(Amersham, UK) of known isotope concentration for quantifica-
tion of autoradiograms. Following development of autoradio-
grams, sections were fixed in methanol and stained with
haematoxylin and eosin (H&E).
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Analysis of blood flow results
Blood flow to the tumour and normal tissues was calculated
in ml g1 min1 from the tissue counts measured via either
autoradiography or gamma counting, the equilibrium partition
coefficient of IAP in the different tissues and the arterial input
function derived from the arterial blood counts. The mathematical
model used was adapted from Kety (1960) and is described
elsewhere in detail (Tozer et al, 1994). Perfusion pressure for all
tissues was assumed to change in direct proportion to MABP, and
changes in tissue vascular resistance (TVR) following treatment,
for the tumour and normal tissues, were calculated from the
changes in MABP divided by the changes in blood flow rate.
A single blood flow value was obtained for each tissue, where
counts were obtained by gamma counting. Autoradiographic
images were captured by camera and transformed pixel by pixel
into blood flow rate images using the same principles as described
above. Analysis was performed using in-house software developed
using the Visilog Image Processing package (Noesis, Orsay,
France). Blood flow autoradiogram images were overlaid onto
histological images from H&E-stained sections to exclude necrotic
regions from the calculations of blood flow. Tumour peripheral
regions were defined as the rim of the tumour equal to 10% of the
section diameter, the remaining portion of the section being
defined as the central region.
Spatial distribution of ET-1 receptors
Distribution of ETA and ETB receptors in untreated P22 tumours
was assessed on sections of the same tumours as used for the blood
flow determination. Preliminary experiments were carried out to
determine suitable incubation concentrations of compounds and
suitable incubation and washing times to maximise specific
binding (data not shown). Slides containing serial pairs of tumour
sections were incubated in wash buffer (50 mM Tris/HCl buffer, pH
7.4, containing 100 mM NaCl, 5 mM MgCl2, 40 mg l
1 bacitracin, 1%
BSA) (15 min, room temperature) to remove endogenous peptides,
drug and 14C-IAP. Sections were dried at room temperature in air,
then incubated for 90 min with 125I-ET-1 (0.13 nM) plus phospho-
ramidon (to inhibit action of endothelin/converting enzyme; 1 mM)
(a) alone (to give total binding ETAþ ETB), or with the addition of
either (b) BQ-788 (ETB receptor antagonist; 100 nM; to give total
ETA binding), or (c) BQ-610 (ETA receptor antagonist, 100nM; to
give total ETB binding). The further inclusion of cold ET-1 (1 mM)
to each group allowed the determination of nonspecific binding
in each case. After incubation, sections were rinsed three times
in wash buffer, dried in air and exposed to Hyperfilm-3H
(Amersham) for 24 h alongside 125I-microscales. Hyperfilm-3H
has no scratch-resistant coating and is therefore suitable for
detection of Auger electrons, which are emitted in addition to
gamma-rays during the decay of 125I. Exposure of test sections for
varying times showed that 24 h was the optimum time for
obtaining grey levels that covered the dynamic range of the film.
Autoradiograms were developed and sections fixed in methanol
and stained with haematoxylin and eosin.
Quantitation of receptor binding
Levels of radioactivity in the 125I-microscales were converted to
total and nonspecific binding (fmol mg1 protein) using the
specific activity of the 125I-microscales supplied by the manufac-
turer (Amersham). These modified scales were used to generate
standard curves from which optical density of the images of the
tumour sections were transformed into total, specific and
nonspecific binding images. Specific binding for each pair of
sections used for receptor studies was calculated by subtraction of
the mean nonspecific binding from the mean total binding using
the whole sections as the region of interest. Image analysis was
carried out using in-house software developed using the Visilog
Image Processing package.
Statistical analysis
The radiotracer blood flow data were tested for normality of
distribution. Differences between groups were tested using a one-
way analysis of variance (ANOVA) followed by a Tukey–Kramer
post-test; P-values less than 0.05 were taken as indicative of
significant differences between groups. Data are presented as
arithmetic means7s.e. (standard error of the mean). Temporal
blood flow changes for the radiotracer data were analysed using
linear regression and the computed curves were compared for
significance using ‘overall test for coincidence of the two
regression lines’ (Glantz, 2002). Laser Doppler data were fitted to
a multivariate model (MANOVA) with repeated measures, in order
to determine the effect of treatment. Responses were fitted to
effects using least squares. Differences in responses due to
treatment or time were tested for significance using an approxi-
mate F-test (JMP Statistics Version 5 for the Apple Macintosh, SAS
Institute Inc., Cary, NC, USA). Differences in response were
described as significant, if the probability corresponding to the
F-value was o 0.05.
RESULTS
RBC flux
Treatment with IRL 1620 at a dose of 3 nmol kg1 decreased RBC
flux immediately after injection, as measured by Laser Doppler
flowmetry in both tumour models (Figure 1). The response pattern
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Figure 1 Time course of relative RBC flux changes after i.v. treatment
with IRL 1620 (3 nmol kg1) (100% is the value in control tumours at the
time of IRL 1620 injection) in P22 (A) and HSN (B) tumours. Each point
represents arithmetic mean7s.e. for six animals. A significant difference
from control is represented by (*).
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was similar in the two tumours, with the effect most pronounced at
5–10 min after the IRL 1620 injection. RBC flux in P22 tumours
was decreased by 50% and in HSN tumours by 60% of
pretreatment values and the recovery to pretreatment value was
somewhat quicker in HSN tumours (approximately 25 min
following IRL 1620 injection for HSN compared to approximately
35 min for P22 tumours).
Blood pressure and heart rate (HR)
Mean arterial blood pressure and HR of anaesthetised BDIX
tumour-bearing rats were measured simultaneously with blood
flow determinations. Mean arterial blood pressure was signifi-
cantly increased 15 and 30 min after IRL 1620 administration, with
no significant change at 5 min (Figure 2A). The opposite pattern
was observed for HR, with a significant effect only occurring at
15 min after treatment (Figure 2B).
Blood flow and vascular resistance
Absolute blood flow to the P22 tumour and a range of normal
tissues in anaesthetised saline-treated BDIX rats is presented in
Table 1. Tumour blood flow was similar to that of blood flow to
muscle, lower compared to that of brain, kidney, spleen and small
intestine, but higher compared to that of skin. Blood flow to skin
overlying tumour was significantly higher than that to contra-
lateral skin, which indicates that tumour has a significant vascular
influence on surrounding tissue.
A similar pattern of blood flow response in the P22 tumour was
obtained using uptake of 125I-IAP as for RBC flux (comparison of
Figures 1 and 3). Tumour blood flow following IRL 1620
administration was reduced to 20% of the control value by 5 min
after treatment (Figure 3). Thereafter, tumour blood flow slowly
recovered to 65% of control blood flow at 15 min, and to control
values at 30 min after treatment. IRL 1620 had no significant effects
on blood flow to brain, heart, contralateral skin and spleen. That is,
regression lines fitted to experimentally obtained blood flow data
from saline-treated control animals and animals treated with IRL
1620 did not differ for these tissues (NS in Figure 3). Blood flow to
tissues in saline-treated rats did not change significantly over the
time course of the experiments (data not shown). Reduction in flow
to skin overlying tumour relative to controls was small, but
statistically significant. The most sensitive normal tissues were
skeletal muscle, kidney and small intestine. Blood flow to muscle was
reduced to B40% and remained at that level 30 min postdrug
administration. Responses of kidney and small intestine to treatment
with IRL 1620 were similar to that of tumour, although recovery was
less apparent, with blood flow to these two tissues remaining at
B70% of control blood flow at 30 min postdrug (Figure 3).
Changes in vascular resistance were calculated for tumour and
all normal tissues (Figure 4). Tumour vascular resistance at 5 min
postdrug injection increased by a factor of 5.5 and was greater than
that achieved in any normal tissues at that time. Thereafter,
tumour vascular resistance decreased and reached control values
at 30 min postdrug injection. Treatment of animals with IRL 1620
did not change the vascular resistance in brain, heart and spleen
compared to control saline-treated animals. Vascular resistance in
kidney and small intestine was increased at all time points, byB4-
fold at 5 and 15 min and two-fold at 30 min following IRL 1620
administration. At all time points, there was a small, but significant
increase in vascular resistance in skin overlying tumour and
contralateral skin. Vascular resistance in the skeletal muscle was
also increased at all time points, with a maximum increase (7.5-
fold) at 15 min following IRL 1620 administration, which was
much greater than any other tissue, including the tumour, at this
time point. This difference in time course of vascular effect in
skeletal muscle implies different binding kinetics in this tissue
compared with the other tissues studied.
Spatial distribution of blood flow
Spatial distribution of tumour blood flow was determined in
control tumours and 5 and 20 min following IRL 1620 adminis-
tration (Figures 5 and 6). Blood flow to tumours from control
saline-treated animals tended to be higher at the edge compared to
the centre of tumour (Figure 6), but when analysed using our
definitions of periphery and centre (Materials and Methods and
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Figure 2 Changes in mean arterial blood pressure (A) and HR (B) of
P22 tumour-bearing control-untreated and IRL-treated rats. Each bar
represents arithmetic mean7s.e. for three to six animals. A significant
difference from control is represented by (*).
Table 1 Tumour and tissue blood flow in saline-treated BDIX rats
bearing P22 tumour
Tissue
Blood flow (AM7s.e.a
(ml g1 min1))
P-value compared to
tumour blood flow
Tumour 0.4270.02
Skin overlying
tumour
0.2070.02 o0.05
Contralateral skin 0.1470.01 o0.05
Skeletal muscle 0.4170.05 40.05
Brain 1.4370.10 o0.05
Heart 3.4470.38 o0.05
Kidney 4.7270.51 o0.05
Spleen 2.4270.24 o0.05
Small intestine 1.2270.09 o0.05
aArithmetic mean7standard error of the mean.
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Figure 5), this difference was not statistically significant. Treat-
ment with IRL 1620 reduced blood flow uniformly throughout the
tumour at 5 min post-treatment with a return to control values by
20 min (Figures 5 and 6). Tumour blood flow changes in frozen
tumour sections did not entirely follow the changes observed in
RBC flux and tumour blood flow measured by the 125I-IAP
method. Tumour blood flow, measured by autoradiography 5 min
after drug administration, was reduced to 25% of control blood
flow, which is in accordance with the data obtained by the 125I-IAP
uptake method. However, this is a larger effect than that measured
by Laser Doppler flowmetry, which showed that RBC flux was
reduced to 50% of the pretreatment values at this time. This
difference may reflect the fact that the IAP technique is primarily
measuring plasma flow rather than RBC flux, although this
explanation remains speculative in the absence of data from a
direct comparison of these techniques. In contrast, 20 min after
treatment, the blood flow measured on frozen tumour sections had
returned to control values, while RBC flux and blood flow
measured with 125I-IAP method were still at B70% of pretreat-
ment value. It is difficult to provide an explanation for this
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Figure 3 Time course of relative blood flow changes in P22 tumour and
normal tissues of BDIX rats following i.v. administration of IRL 1620 at a
dose of 3 nmol kg1 plotted as % of the value in time-matched saline-
treated rats. Each time point represents arithmetic mean7s.e. for three to
six animals. P-values represent significance levels for statistical comparisons
of curves obtained from drug-treated and saline-treated rats (see Materials
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Each time point represents arithmetic mean7s.e. for three to six animals.
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difference apart from invoking intertumour heterogeneity of
response, perhaps related to the different tumour transplantations
used in the various experiments.
Receptor distribution
The distribution of total (ETAþETB) and ETA binding tended to
be higher in the tumour periphery compared to tumour centre, but
this was not statistically significant (Table 2, Figure 7). The
distribution of ETB receptor binding was homogeneous through-
out the tumour section, which represents a major difference from
the discrete patches of ETB binding previously observed for the
HSN tumour (Bell et al, 1998). A high level of specific binding was
observed for total (ETAþETB) and ETA receptor binding with 78
and 85% specific binding, respectively, compared with 51%
specific binding for ETB receptors.
DISCUSSION
IRL 1620 caused a profound short-term reduction of blood flow in
the P22 tumour, in the face of an increase in MABP, indicative of
IRL 1620-induced tumour vasoconstriction. These results show
that the P22 tumour vasculature is responsive to the ETB receptor
agonist IRL 1620 and provide indirect evidence for fully functional
ETB receptors on the tumour vasculature. In order to fully
demonstrate that ETB receptors are localised on blood vessels,
double immunostaining using specific antibodies for blood vessels
and ETB receptors would be necessary. Profound vasoconstriction
of the P22 tumour in response to IRL 1620 occurred uniformly
throughout the tumour mass, at levels equivalent to or greater than
that found in normal tissues. Receptor binding studies revealed
existence of both ETA and ETB receptors in the P22 tumour and
showed that ETA receptors are more abundant than ETB receptors,
which may be significant for tumour growth. The activation of ETB
receptors on endothelial cells results in vasodilation via activation
of the nitric oxide pathway, so that the decrease in blood flow and
increase in vascular resistance in the P22 tumour following
treatment with IRL 1620 indicate that the predominant vasoactive
component of ETB receptors is localised on contractile elements
rather than on endothelial cells. IRL 1620 caused vasoconstriction
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Figure 5 Absolute blood flow across tumour section at 5 and 20 min
following i.v. treatment with IRL 1620 at a dose of 3 nmol kg1. Each bar
represents arithmetic mean7s.e. for three to six animals. A significant
difference from pertinent control (whole, periphery or centre) is
represented by (*).
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Figure 6 Representative computed images of control P22 tumour blood flow (A), at 5 min (B) and 20 min (C) following i.v. treatment with IRL 1620 at a
dose of 3 nmol kg1.
Table 2 Receptor binding in P22 tumour sections
Specific receptor binding
Wholea Peripheryb Centrec
Binding site n
AM7s.e.d (fmol mg1
protein)
% of total
binding
AM7s.e. (fmol mg1
protein)
% of total
binding
AM7s.e. (fmol mg1
protein)
% of total
binding
ETA+ETB
e 12 6.671.8 78 7.172.1 78 6.370.9 79
ETA
f 12 6.772.0 85 7.372.1 85 6.172.0 85
ETB
g 12 1.770.4 51 1.770.4 49 1.670.4 51
ETA¼ endothelin A; ETB¼ endothelin B. aBinding of ligands to whole tumour section. bBinding of ligands to peripheral tumour region. cBinding of ligands to central tumour
region. dArithmetic mean7standard error of the mean. eBinding of 125I-ET-1 to tumour section. fBinding of 125I-ET-1 with the addition of BQ-788 to tumour section. gBinding of
125I-ET-1 with the addition of BQ-610 to tumour section.
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in skeletal muscle, kidney and small intestine, as well as in tumour,
but did not affect blood flow in other normal tissues such as skin,
brain, heart and spleen. The relatively short duration of
vasoconstriction in both tumour and normal tissues is presumably
a reflection of both rapid plasma clearance and receptor binding
kinetics in the different tissues.
In our previous studies investigating the blood flow-modifying
effects of endothelin receptor ligands, such as ET-1 itself,
sarafotoxin and IRL 1620 in the HSN tumour model, IRL 1620
was the most promising for selective reduction in tumour blood
flow with minimal effects on systemic blood pressure and blood
flow in the majority of normal tissues (Bell et al, 1995, 1999). In the
present study, the profound vasoconstrictive capacity of IRL 1620
was demonstrated in a second tumour type and a full time course
of events determined. In addition, some differences between the
responses in the two model systems can be described. In contrast
to responses of normal tissues of CBH/CBi rats to the action of
3 nmol kg1 IRL 1620, where reduced blood flow was observed
only in small intestine (Bell et al, 1999), the same dose of IRL 1620
in the current study using BDIX rats induced a significant blood
flow reduction in kidney and skeletal muscle, as well as small
intestine. This may be explained by a complex dose response for
IRL 1620 in several tissues, as observed in CBH/CBi rats (Bell et al,
1999). For example, 1 nmol kg1 IRL 1620 caused a significant
reduction in blood flow rate to skeletal muscle despite no effect of
3 nmol kg1. This bell-shaped dose response pattern is most likely
due to desensitisation of receptors at higher doses (Bell et al, 1999)
and the difference between skeletal muscle response in CBH/CBi
rats and BDIX rats to 3 nmol kg1 IRL 1620 is therefore likely to
reflect differences in doses at which this desensitisation occurs,
which may in turn reflect differences in receptor numbers. In
addition, this strain difference in skeletal muscle response is likely
to explain the markedly greater hypertensive effect of IRL 1620 in
BDIX rats compared with that for CBH/CBi rats. In the current
study, kidney blood flow was reduced to a similar level as that in
tumours (despite a somewhat different time course), suggesting
that vasoconstriction in kidney is mediated primarily through the
ETB receptor. This was also suggested by Just et al (2004), although
there is also evidence for some involvement of ETA receptors
(Matsuura et al 1996; Ozawa et al 2003). In the present study, the
response of small intestine to IRL 1620 was also vasoconstrictive,
again indicating that the predominant responsive ETB receptors
in this tissue are on contractile elements of the blood vessels. A
selective blood flow decrease in kidney and small intestine might
be used therapeutically in combination with chemotherapeutic
drugs such as vincristine and 5-fluorouracil, which are primarily
toxic to the gastrointestinal tract or cisplatin, which is toxic to
kidney. In these types of combination, IRL 1620 could be used to
divert blood away from the sensitive tissues and thus lower the
side effects of such treatment.
In a rat breast tumour model, employing a radioactive micro-
sphere technique, treatment of animals with ET-1 resulted in
increased tumour blood flow compared to normal breast tissue in
normal rats. This increase in tumour blood flow was attenuated by
pretreatment with the ETB receptor antagonist BQ788 (Rai and
Gulati, 2003). Therefore, the authors suggested that ETB receptor
agonists could be used to increase blood flow selectively to breast
tumour and consequently increase delivery of anticancer drugs.
This suggestion is in contrast to our current study on the P22
tumour and our previous study on the HSN tumour (Bell et al,
1999), where IRL 1620 decreased blood flow. Indeed, it is possible
to explain the increase in tumour blood flow induced by ET-1 in
the Rai study without invoking a vasodilatory role for ETB
receptors on the tumour vasculature. This could occur as a result
of ET-1-induced hypertension causing an increase in tumour
perfusion pressure combined with a relative lack of constrictive ET
receptors on the tumour vasculature. In our previous study on
HSN and P22 tumours, blood flow to tumours was unmodified by
treatment with ET-1 (Bell et al, 1996). Although this difference
from the Rai study is presumably due to different complements of
ET receptors on the different tissues of the various rat strains,
without more specific information it is not possible to say whether
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Figure 7 Representative computed images of total and non-specific ETAþ B (A), ETA (B) and ETB (C) receptor binding in P22 tumour.
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differences in the receptor complement on the vasculature of
tumours is more important than that on the vasculature of normal
tissues, the latter having a profound influence on systemic blood
pressure response and, therefore, perfusion pressure to the
tumour.
To assess the regional changes in tumour blood flow after
treatment with IRL 1620, we used tumour uptake of 14C-IAP
followed by autoradiography. Blood flow was homogeneously
reduced throughout the tumour section. This is important
information, since angiotensin II, for example, reduced tumour
blood flow only in periphery, with no changes in the blood flow in
the central region of the tumour (Tozer et al, 1996). This is
probably due to the difference in receptor distribution. In the case
of angiotensin II receptors, 10% more binding sites for angiotensin
II were demonstrated at the periphery of P22 tumours than at the
centre (Tozer et al, 1996) compared to homogeneous distribution
of ETB receptors in the current study. This suggests that ETB
receptors are located on the contractile elements of microvessels
in the centre of the P22 tumour. Indeed, pericytes are commonly
found, in close association with microvessels, in the centre of these
tumours (GM Tozer, unpublished data).
Receptor binding studies on cryostat sections of the same
tumours as used in the blood flow analysis showed that the P22
tumour possesses ETA, as well as ETB receptors, with binding sites
distributed relatively homogeneously across the tumour section. A
high degree of specific binding, in the region of 85% of the total
binding, was observed when ETAþETB receptors were observed
together and when ETA receptor binding was performed (in the
presence of the ETB antagonist BQ788). In contrast, a much lower
intensity of ETB receptors was observed in P22 tumour sections (in
the presence of the ETA antagonist BQ610), which corresponded
to a lower level of specific binding (51%). Previous workers have
reported the binding kinetics of ET-1 at ETA and ETB receptors,
and have observed the dissociation constants (Kd) of the ligand to
be similar at each receptor (Ohlstein et al, 1996). This implies that
the difference in the level of specific binding represents a higher
density of ETA receptors than ETB receptors in the P22 tumour,
rather than merely reflecting differences in the selectivity and
affinity of the ligand for each receptor subtype.
ETB receptor binding in the rat HSN tumour was concentrated
in small regions of intense binding (Bell et al, 1998), which
suggested specific vascular localisation. However, the ETB receptor
distribution in P22 tumours was homogeneous and suggests that
ETB receptors are localised on tumour cells as well as on the
vasculature in this tumour type. Similarly, in human glioblastoma
tumours, the pattern of ETB receptor distribution was homo-
geneous suggesting localisation on cancer cells, whereas ETA
receptors were highly expressed in glioblastoma vessels and in
some scattered glioblastoma areas (Egidy et al, 2000). Despite the
difference in the ETB receptor binding site distribution, vascular
resistance in HSN and P22 tumours was increased to approxi-
mately the same degree. Over the whole tumour sections, specific
ETB receptor binding in the P22 tumour was 1.7 fmol mg
1
(Table 2) compared to 0.7 fmol mg1 for the HSN tumour (Bell
et al, 1998). Considering the homogeneous binding distribution in
the P22 tumour, this figure may be a reasonable reflection of
specific binding on the blood vessels. However, the heterogeneous
binding in the HSN tumour suggests that specific binding on the
blood vessels of this tumour may be considerably higher than the
average value suggests. In view of this, the blood flow response of
the two tumour types is reasonably compatible with the binding
results. Considering these results, methods for measuring specific
receptor densities in human tumours, either from biopsies or
using imaging techniques, appear useful for predicting vascular
response to vasoactive agents.
In most human tumours investigated so far, both ET receptor
subtypes have been identified (Nelson et al, 2003), although
pharmacological manipulation of the endothelin axis for cancer
therapy has concentrated on the potential for ETA antagonists
(Nelson, 2001; Nelson et al, 2003; Sonveaux et al, 2004). Our
studies suggest that the ETB agonist, IRL 1620, would be useful for
short-term blood flow reduction in tumours expressing the ETB
receptor and, due to its constrictive effect, IRL 1620 may also have
antiangiogenic properties. It would be important to determine the
effects of this ET-1 agonist in tumours that endogenously produce
high levels of ET-1 such as prostate, breast and ovarian cancers
(Nelson et al, 2003; Grimshaw et al, 2004). Although it might be
expected that exogenous administration of an agonist would have
little effect under these conditions, this is not necessarily the case,
considering that ET receptors are often upregulated in concert
with their ligands (Grimshaw et al, 2004).
In conclusion, our results show that fully functional ETB
receptors are expressed on the vasculature of at least two different
tumours, leading to a relatively selective and profound short-term
reduction of tumour blood flow, following administration of the
ETB receptor agonist, IRL 1620. Expression levels of ETB receptors
on the tumour vasculature could be useful for predicting which
tumours are likely to respond to IRL 1620. The vasoconstriction
produced in the P22 and HSN tumours was equivalent to or greater
than that found for normal tissues and to our knowledge, this is a
unique feature of IRL 1620 compared to other vasoconstrictors,
which tend to be less effective against tumour than normal blood
vessels. The activation of ETB receptors with selective agonists
such as IRL 1620 is therefore promising, with the proviso that
normal kidney, intestine and skeletal muscle are also affected.
Distribution of ETB binding in the P22 tumour suggested ETB
receptor localisation on tumour cells as well as on the vasculature,
which may also be significant for tumour growth. Blood flow
results suggested that the vascular component of ETB receptors is
localised on contractile elements rather than on endothelial cells.
Considering the profound vasoconstrictive effect of a single dose
of IRL 1620 in tumours, further studies are warranted to determine
its effects in a repeated dosing schedule on tumour angiogenesis
and growth, where selectivity of vascular effect for tumours may
not be critical. In addition, further studies using specific ET-1
receptor agonists and antagonists should provide more insight into
the role of the endothelin axis in the tumour vasculature, leading
to the development of specific vascular-targeted therapies.
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